Evasion of apoptosis may contribute to poor treatment response in pediatric acute lymphoblastic leukemia (ALL), calling for novel treatment strategies. Here, we report that inhibitors of apoptosis (IAPs) at subtoxic concentrations cooperate with various anticancer drugs (that is, AraC, Gemcitabine, Cyclophosphamide, Doxorubicin, Etoposide, Vincristine and Taxol) to induce apoptosis in ALL cells in a synergistic manner as calculated by combination index and to reduce long-term clonogenic survival. Importantly, we identify RIP1 as a critical regulator of this synergism of IAP inhibitors and AraC that mediates the formation of a RIP1/FADD/caspase-8 complex via an autocrine/paracrine loop of tumor necrosis factor-a (TNFa). Knockdown of RIP1 abolishes formation of this complex and subsequent activation of caspase-8 and -3, mitochondrial perturbations and apoptosis. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 or blockage of TNFa by Enbrel inhibits IAP inhibitor-and AraC-triggered interaction of RIP1, FADD and caspase-8 and apoptosis. In contrast to malignant cells, IAP inhibitors and AraC at equimolar concentrations are non-toxic to normal peripheral blood lymphocytes or mesenchymal stromal cells. Thus, our findings provide first evidence that IAP inhibitors present a promising strategy to prime childhood ALL cells for chemotherapy-induced apoptosis in a RIP1-dependent manner. These data have important implications for developing apoptosis-targeted therapies in childhood leukemia.
INTRODUCTION
Acute lymphocytic leukemia (ALL) is the most common pediatric malignancy. 1 As the prognosis of children with very high risk or at relapse is still poor in contrast to the overall good prognosis, 1, 2 new strategies are necessary to enhance the efficacy of current treatment options.
Evasion of programmed cell death (apoptosis) represents a characteristic feature of human cancers including leukemia and can confer treatment resistance, as most anticancer therapies exert their cytotoxic action by inducing cell death, namely apoptosis, in cancer cells. 3 --5 Apoptosis signaling pathways can be divided into two major routes, that is, the death receptor (extrinsic) and the mitochondrial (intrinsic) pathway, which result in activation of caspases as a common downstream effector mechanism. 5 Activation of receptors of the tumor necrosis factor (TNF) receptor superfamily, including CD95 (APO-1/Fas), TNF-related apoptosis-inducing ligand receptors or TNF receptor 1, triggers caspase-8 activation in a multimeric complex including the adaptor protein FADD and subsequent cleavage of downstream effector caspases such as caspase-3. 6 Within the intrinsic (mitochondrial) pathway, cytochrome c and second mitochondriaderived activator of caspase (Smac)/direct inhibitor of apoptosis-(IAP) binding protein with low PI (DIABLO) are released from mitochondria, which in turn trigger caspase-3 activation via the apoptosome complex (cytochrome c) and by binding to X-linked inhibitor of apoptosis (XIAP), respectively. 7 IAP proteins are a family of eight proteins that all harbor a BIR domain. 8 In addition, a RING domain with E3 ubiquitin ligase activity is found in some IAP proteins, that is, XIAP, cIAP1 and cIAP2, which can mediate (auto)ubiquitination and proteasomal degradation. 8 Among the IAP family members, XIAP is best characterized for its antiapoptotic function by binding to and inhibiting effector caspase-9 and -3/-7 via its BIR3 domain and the linker region preceding BIR2 domain, respectively. 9 Recently, cIAP1 and cIAP2 were identified as E3 ubiquitin ligases for the serin/threonin kinase RIP1 that put K63-linked ubiquitin chains on RIP1.
10 RIP1 can modulate cell death and survival pathways, depending, for example, on its ubiquitination status.
11 LysK63-ubiquitinated RIP1 promotes NF-kB activation, whereas deubiquitinated RIP1 allows the formation of a RIP1/FADD/caspase-8 complex.
11 Smac mimetics have recently been shown to trigger autoubiquitination and proteasomal degradation of IAP proteins with a RING domain 12 --14 and, thus, can indirectly modify the ubiquitination status of RIP1. 10 Highly increased expression of XIAP protein associated with poor outcome has previously been reported in childhood ALL compared with control bone marrow. 15 Also, high levels of cIAP1 protein were found in pediatric acute leukemia samples. 16 We previously reported that small molecule IAP inhibitors enhance TNF-related apoptosis-inducing ligand-or Fas ligand-induced apoptosis in childhood leukemia. 17 However, the question whether targeting IAP proteins represents also a suitable strategy to prime acute leukemia cells for chemotherapy-induced apoptosis has not yet been answered. Therefore, we investigated in the present study the effect of small molecule IAP inhibitors on anticancer drug-induced apoptosis in childhood acute leukemia.
MATERIALS AND METHODS

Cell culture
Human T-ALL (Jurkat, CEM) and precursor (pre)-B-ALL (Reh, Nalm-6) cell lines were obtained from ATCC (CEM, Manassas, VA, USA) or DSMZ (Jurkat, Reh, Nalm-6; Braunschweig, Germany) and were cultured as described previously. 17 IAP inhibitor 1, IAP inhibitor 2 and control compound were kindly provided by Idun Pharmaceuticals now Pfizer, Inc. (Groton, CT, USA) and correspond to compounds 2, 11 and 15, respectively, described by Oost et al.
18 IAP inhibitor 3 was described by Chao et al. 19 Caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) was obtained from Bachem (Heidelberg, Germany), TNFa and Necrostatin-1 (Nec-1) were purchased from Biomol (Hamburg, Germany). Enbrel was kindly provided by Pfizer. All chemicals were purchased by Sigma (Steinheim, Germany) unless indicated otherwise.
Analysis of primary leukemic blasts
Leukemia blasts were derived from children treated for ALL at the Ludwig Maximilians University's children's hospital after informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the local Ethical Committee. Characteristics of patients are summarized in Table 1 . Samples were obtained by bone marrow puncture at initial diagnosis before the onset of therapy, isolated using Ficoll Isopaque (Amersham Bioscience, Freiburg, Germany) and stimulated directly after isolation. Apoptosis was determined by forward side scatter analysis and flow cytometry. The percentage of specific apoptosis was calculated as follows: 100 Â [experimental apoptosis (%)---spontaneous apoptosis (%)]/[100%---spontaneous apoptosis (%)].
Lentiviral transduction of short hairpin RNA (shRNA) Double-stranded oligonucleotides encoding shRNAs specific for RIP1, cIAP1 and a non-sense shRNA (control) were ligated into the pGreenPuro vector (control: gatcatgtagatacgctca; shRIP1: ccactagtctgacggataa; shcIAP1-1: gagaagaggagaaggaaaa; shcIAP1-2: ggatccacctctaagaata). pGreenPuroshRNA constructs were transfected into 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) together with pRSV-Rev, pMDLg /pRRE and pMD2.G plasmids. After 72 h, the lentivirus-containing supernatant was collected, filtered and cells were spin-infected in the presence of 8 mg/ml polybrene (Sigma). Stable bulk cultures were generated by selection with 1 mg/ml puromycin (BD Sciences, Heidelberg, Germany).
Western blot analysis
Western blot analysis was performed as described previously 20 using the following antibodies: mouse anti-caspase-8 (1:1000) from Alexis Biochemicals (Epalinges, Switzerland), rabbit anti-caspase-3 (1:1000; Cell Signaling, Beverly, MA, USA), rabbit anti-caspase-9 (1:1000), mouse anti-XIAP, mouse anti-FADD and mouse anti-RIP1 (1:1000) from BD Biosciences (Heidelberg, Germany), goat anti-cIAP1 (1:1000) and rabbit anti-survivin (1:1000) from R&D Systems, Inc. (Wiesbaden, Germany), rabbit anti-cIAP2 (1:1000; Epitomics, Burlingame, CA, USA), mouse anti-livin (1:1000; Imgenex, San Diego, CA, USA), or mouse anti-b-actin as loading control (1:5000; Sigma) followed by goat-anti-mouse IgG, goat-anti-rabbit IgG or donkey-anti-goat IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Enhanced chemiluminescence was used for detection (Amersham Bioscience). All western blots shown are representative of at least three independent experiments.
Determination of apoptosis and clonogenic survival
Apoptosis was determined by fluorescence-activated cell sorting analysis (FACScan, BD Biosciences) of DNA fragmentation of propidium iodidestained nuclei or by forward side scatter analysis as described previously. 
Immunoprecipitation
Cells were lysed in NP40 buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, supplemented with a protease inhibitor tablet (Roche, Grenzach, Germany). In all, 2 mg of protein was incubated with 20 mg mouse anti-Caspase-8 antibody (Alexis, Grü nberg, Germany) overnight at 4 1C followed by the addition of 10 ml pan-mouse IgG Dynabeads (Invitrogen), then incubated for 2 h at 4 1C and washed with NP40 buffer. Caspase-8 was detected using rabbit monoclonal anti-Caspase-8 antibody (Epitomics), RIP1 or FADD with anti-mouse RIP antibody or mouseanti-FADD antibody (BD Biosciences).
Determination of mitochondrial membrane potential and cytochrome c release Mitochondrial membrane potential and cytochrome c release were determined as previously described. 21, 22 Determination of TNFa secretion Reh cells were seeded in a 96-well plate (2 Â 10 6 cells/ml) and treated with AraC and/or IAP inhibitor 2 or DMSO for indicated times. TNFa secretion was measured by bead-based immunoassay using a Fluorokine MAP cytokine multiplex kit (R&D Systems) and a BioPlex analyzer (BioRad, Munich, Germany).
Statistical analysis
Statistical significance was assessed by Student's t-test, using Winstat (R. Fitch Software, Bad Krozingen, Germany) software. Drug interactions were analyzed by the Combination index method based on that described by Chou 23 using CalcuSyn software (Biosoft, Cambridge, UK). Combination index o0.9 indicates synergism, 0.9 --1.1 additivity and 41.1 antagonism. Abbreviations: ALL, acute lymphoblastic leukemia; c-ALL, common ALL; pre-B-ALL, B-cell precursor ALL; T-ALL, T-cell ALL.
a Number of patient sample corresponding to samples shown in Figure 1f , no clinical data are available for samples no. 1 and no. 5.
RESULTS
IAP inhibitors sensitize acute leukemia cells to chemotherapyinduced apoptosis
To investigate the potential of small molecule IAP inhibitors to augment chemotherapy-induced apoptosis in ALL cells, we assessed apoptosis upon treatment with various anticancer drugs in the presence or absence of an IAP inhibitor using the B-cell precursor ALL cell line Reh. Of note, the IAP inhibitor significantly enhanced apoptosis following exposure to several cytotoxic drugs, including AraC, Gemcitabine, Cyclophosphamide, Doxorubicin, Etoposide, Vincristine and Taxol (Figure 1a, Supplementary Figure  1A) . To exclude that this observation is restricted to one particular cell line or a specific IAP inhibitor, we extended our study to additional cell lines and structurally distinct IAP inhibitors. Different IAP inhibitors at subtoxic concentrations significantly increased AraC-induced apoptosis in a dose-dependent manner in several ALL cell lines ( Figure 1a ). We previously reported that IAP inhibitors as single agents triggered apoptosis in a dosedependent manner in leukemia cells. 17 In contrast, a close structural analogue that only weakly binds to the BIR3 domain of XIAP 18 that served as control had no effect on AraC-induced apoptosis compared with solvent demonstrating the specificity of the sensitizing effect ( Figure 1a Table 1 ). Kinetic analysis showed that the IAP inhibitor enhanced AraC-induced apoptosis in a time-dependent manner ( Figure 1c) . Induction of apoptotic cell death by IAP inhibitor and AraC was confirmed by analysis of DNA fragmentation as a biochemical hallmark of apoptosis ( Figure 1d ). In addition to short-term apoptosis assays, we also assessed the effect of IAP inhibitor on long-term clonogenic survival. Importantly, IAP inhibitor 2 acted in concert with AraC to reduce clonogenic growth of leukemia cells ( Figure 1e ). Furthermore, IAP inhibitor 2 increased AraC-induced apoptosis in primary leukemic blasts, including blasts of patients with high-risk disease ( Figure 1f , Table 1 ).
To investigate whether IAP inhibitors in combination with AraC are cytotoxic to normal cells, we assayed peripheral blood lymphocytes as well as normal human hematopoietic and mesenchymal stromal cells (MSCs) that were isolated from healthy donors. Unstimulated and activated peripheral blood lymphocytes 6 days after stimulation with phytohemoagglutinin and MSCs were refractory towards treatment with equimolar concentrations of IAP inhibitors alone or in combination with AraC (Supplementary Figure 3A -C), demonstrating that the combination of AraC and IAP inhibitor is non-toxic to normal peripheral blood lymphocytes or MSCs at concentrations that trigger apoptosis in leukemia cells. Furthermore, the addition of IAP inhibitor did not increase the cytotoxicity of AraC against human CD34 þ peripheral blood mononuclear cells (Supplementary Figure 3D) .
Together, this set of experiments demonstrates that IAP inhibitors sensitize ALL cells to chemotherapy-induced apoptosis, resulting in suppression of clonogenicity. As AraC was one of the chemotherapeutic drugs that displayed high synergistic activity together with IAP inhibitors, we selected this drug for further mechanistic studies.
IAP inhibitor enhances AraC-induced, caspase-dependent mitochondrial perturbations To gain insight into the underlying mechanisms of the synergism of IAP inhibitors and AraC in leukemia cells, we examined signaling via the mitochondrial pathway, which has been implied in chemotherapy-induced apoptosis. 5 Addition of IAP inhibitor 2 significantly increased loss of mitochondrial membrane potential and the release of cytochrome c from mitochondria in a timedependent manner, while treatment with AraC alone exerted minimal effects on these events (Figures 2a and b) . Further, IAP inhibitor 2 substantially enhanced AraC-induced processing of caspase-3, -8 and -9 into active cleavage fragments ( Figure 2c , Supplementary Figure 4) . Inhibition of caspase activity by the broad-range caspase inhibitor zVAD.fmk completely prevented the IAP inhibitor-mediated increase in AraC-induced apoptosis (Figure 2d) . Also, zVAD.fmk almost completely inhibited drop of mitochondrial membrane potential and cytochrome c release in cells treated with the combination of IAP inhibitor 2 and AraC (Figures 2a and b) , demonstrating that caspase activity is required for mitochondrial perturbations during IAP inhibitor-and AraCinduced apoptosis.
An autocrine/paracrine TNFa loop contributes to IAP inhibitor-and AraC-induced apoptosis As apoptosis triggered by monotherapy with IAP inhibitors has been attributed to a TNFa-driven autocrine cell death loop, 10, 12, 13, 24 we investigated whether TNFa mediates apoptosis that is induced by subtoxic doses of IAP inhibitor in combination with AraC. Indeed, IAP inhibitor and AraC cooperated to stimulate TNFa release (Figure 3a) . Addition of the TNFa-blocking antibody Enbrel reduced activation of caspase-8 and -3, loss of mitochondrial membrane potential and apoptosis upon treatment with the IAP inhibitor and AraC (Figures 3b-d) . To confirm that TNFa exerts a pro-apoptotic function in this model of cell death, we assessed the effect of exogenously added TNFa on apoptosis induction by IAP inhibitor and/or AraC. Interestingly, TNFa cooperated with either IAP inhibitor or AraC to induce apoptosis (Figure 3e ). Also, TNFa further enhanced apoptosis by the combination treatment of IAP inhibitor and AraC (Figure 3e ). Moreover, Enbrel inhibited IAP inhibitorinduced apoptosis in a concentration-dependent manner with better inhibition the higher the IAP inhibitor concentrations (Figure 3f ). Together, these findings indicate that TNFa in part contributes to the induction of apoptosis by IAP inhibitor and AraC.
IAP inhibitor-mediated downregulation of cIAP1 contributes to AraC-induced apoptosis As IAP inhibitors initiate autoubiquitination and proteasomal degradation of IAP proteins harboring a RING domain with E3 ligase activity, 10,12 --14 we next analyzed the effect of the IAP inhibitor on expression levels of IAP proteins. Exposure to IAP inhibitor 2 caused rapid downregulation of cIAP1, whereas no effect was observed on expression levels of XIAP, Livin or Survivin (Figure 4a ). By comparison, cIAP2 expression is barely detectable in ALL cell lines. 17 Combination treatment with IAP inhibitor 2 and AraC further decreased expression levels of cIAP1 compared with exposure to IAP inhibitor 2 alone and also caused downregulation of Livin expression by proteolytic processing (Figure 4b and data not shown). To explore the functional relevance of cIAP1, we knocked down its expression by RNA interference. Silencing of cIAP1 significantly increased AraC-induced apoptosis as well as apoptosis triggered by AraC and IAP inhibitor 2 (Figure 4c ), demonstrating that downregulation of cIAP1 promotes AraCmediated apoptosis. Also, knockdown of XIAP significantly enhanced AraC-mediated apoptosis (Supplementary Figure 5) .
RIP1 is a critical mediator of IAP inhibitor-and AraC-induced apoptosis As cIAPs have recently been identified as E3 ligases that ubiquitinate and, thus, modulate RIP1 function, 10 we next explored whether RIP1 is required for cell death induced by IAP inhibitor and AraC. Importantly, RNA interference-mediated knockdown of RIP1 profoundly attenuated the IAP inhibitor 2-mediated sensitization towards AraC-induced apoptosis (Figure 5a) . Similarly, RIP1 deficiency 25 prevented sensitization to AraC-mediated apoptosis by IAP inhibitor 2 (Supplementary Figure 6) . To exclude that this observation was restricted to AraC, we extended these experiments to additional anticancer drugs. Similarly, RIP1 knockdown inhibited the IAP inhibitor 2-mediated increase in apoptosis upon treatment with Gemcitabine, Doxorubine, Vincristine and Etoposide (Figure 5b) .
To unveil the underlying molecular mechanisms we examined the interaction of RIP1 and caspase-8 by immunoprecipitation, because of the ubiquitination status of RIP1 has recently been shown to modulate the recruitment of RIP1 to caspase-8.
10,14 The IAP inhibitor 2 stimulated the formation of a RIP1/FADD/caspase-8 complex, which was further enhanced in the presence of AraC (Figure 5c ). Knockdown of RIP1 abolished the formation of this complex (Figure 5c ), demonstrating that RIP1 is required for the caspase-8/FADD interaction. Our finding that partial knockdown of RIP1 results in undetectable levels of RIP1 in caspase-8 immunoprecipitates indicates that low levels of RIP1 may be insufficient for the formation of the RIP1/caspase-8/FADD complex, in line with another recent report. 14 As we found that RIP1 controls the recruitment of caspase-8 and FADD into a multimeric complex, we next investigated whether RIP1 is proximal to activation of the caspase cascade. Strikingly, RIP1 knockdown prevented cleavage of caspase-8 and caspase-3 into active fragments upon treatment with the IAP inhibitor 2 and AraC (Figure 5d ). Additionally, RIP1 silencing significantly reduced loss of mitochondrial membrane potential (Figure 5e ). This demonstrates that activation of the caspase cascade and mitochondrial perturbations occur in a RIP1-dependent manner.
In addition to genetic silencing, we employed a pharmacological approach to antagonize RIP1 using Necrostatin-1, a selective allosteric RIP1 inhibitor. 26, 27 Similarly, Necrostatin-1 significantly and AraC (Figure 6b) , consistent with the requirement of RIP1 kinase activity in this model of apoptosis (Figure 6b) .
To investigate whether TNFa stimulates the formation of the RIP1/ FADD/caspase-8 complex, we examined the effect of TNFa blockage by Enbrel on the recruitment of RIP1 and FADD to caspase-8. Enbrel substantially diminished the formation of the RIP1/FADD/caspase-8 complex (Figure 6b) . Together, this set of experiments demonstrates that RIP1 has a key role in mediating the cooperative induction of apoptosis by IAP inhibitor 2 and AraC in ALL cells.
DISCUSSION
As defective apoptosis programs contribute to the poor response of children with high-risk ALL, 4 new concepts to activate the apoptotic machinery in childhood ALL are required. Here, we provide for the first time evidence that IAP inhibitors present a promising novel strategy to prime childhood ALL cells for chemotherapy-induced apoptosis. This conclusion is based on the following independent pieces of evidence: First, IAP inhibitors at subtoxic concentrations, but not a structurally related control compound, cooperate with several anticancer drugs that are commonly used in the treatment of pediatric ALL to trigger apoptosis in a synergistic manner as calculated by combination index. Second, IAP inhibitors act in concert with chemotherapeutics to suppress colony formation demonstrating an effect also on long-term clonogenic survival. Third, we identify a novel mechanism of action underlying this cooperative interaction of IAP inhibitors and anticancer drugs, that is, RIP1-triggered drugs by demonstrating that the serine/threonine kinase RIP1 has a critical role in this model of apoptosis. This is supported by several lines of evidence. First, knockdown of RIP1 abolishes the formation of the RIP1/FADD/caspase-8 signaling complex and profoundly inhibits subsequent activation of caspase-8 and -3, loss of mitochondrial membrane potential and apoptosis. Second, this rescue from chemotherapy-induced apoptosis by RIP1 silencing is found for various anticancer drugs (for example, AraC, Doxorubicin, Etoposide, Vincristine and Gemcitabine), pointing to a more general mechanism that is not specific for a single compound and thus, is likely of broader relevance for cancer therapy. Third, inhibition of RIP1 kinase activity by the specific small molecule inhibitor Necrostatin-1 similarly inhibits formation of the RIP1/FADD/caspase-8 complex as well as apoptosis indicating that the kinase activity of RIP1 is required for the recruitment of caspase-8 and FADD to RIP1. This finding is in line with a recent report showing that a kinase dead mutant form of RIP1 fails to mediate TNFa plus Smac mimetic-induced apoptosis. 14 The critical targets that are phosphorylated by RIP1 in this model of apoptosis are not yet known and their identification is the subject of future studies.
The formation of this RIP1/FADD/caspase-8 complex and apoptosis in response to IAP inhibitor and AraC partly involves an autocrine or paracrine acting loop of TNFa, as the combination treatment leads to increased TNFa release. In addition, the TNFablocking antibody Enbrel reduces formation of this complex, caspase activation, mitochondrial perturbation and apoptosis. Moreover, exogenously added TNFa further enhances apoptosis by the combination treatment of IAP inhibitor and AraC. However, TNFa-independent mechanisms might also have a role in the synergistic induction of apoptosis by IAP inhibitor and AraC, as Enbrel did not completely block the formation of the RIP1/FADD/ caspase-8 complex and apoptosis. As the IAP inhibitors antagonize XIAP besides cIAP1 and cIAP2, 18 the neutralization of the XIAPimposed inhibition of effector caspases by IAP inhibitors might contribute to promote IAP inhibitor-and AraC-induced apoptosis, as we recently reported for death receptor-induced apoptosis. 17, 28 Also, our findings indicate that DNA damage might promote RIP1/FADD/caspase-8 formation independently of autocrine/paracrine TNFa signaling.
Our findings have important implications for the future development of IAP inhibitor-based treatment strategies in childhood ALL. Recently, high XIAP protein expression was found in childhood ALL cells compared with bone marrow mononuclear cells and correlates with poor prednisone response in children with T-cell ALL, 15 indicating that XIAP presents a relevant therapeutic target in pediatric ALL. Preclinical studies from our lab and other investigators indicate that only a subset of cancer cell lines or primary tumor samples are susceptible to single agent treatment with IAP inhibitors/Smac mimetics. 12,17,24,29 --31 This suggests that these inhibitors might clinically best be exploited in combination protocols, underscoring the relevance of identifying and developing IAP inhibitor-based combination strategies. Thus, by demonstrating that IAP inhibitors synergize with various cytotoxic drugs that are commonly used in the treatment of pediatric ALL to trigger apoptosis and to inhibit long-term clonogenic survival, our study has important implications for the future clinical application of IAP inhibitors in childhood ALL. In this respect, it is important to note that we found no sensitization of normal lymphocytes, MSCs or CD34 þ cells for chemotherapyinduced cell death by IAP inhibitors in contrast to leukemia cells.
Another important aspect relates to the fact that the cooperative interaction between IAP inhibitors and chemotherapeutics to induce apoptosis occurred especially at subtoxic concentrations, indicating that IAP inhibitors may be used in chemotherapy protocols to reduce the dose of cytotoxic drugs that is required for antileukemic activity, which might decrease the risk of chemotherapy-inferred toxic side effects.
Beyond pediatric ALL, the identified molecular mechanism of synergy is also of broader relevance for other cancers and opens new perspectives for the use of IAP inhibitors in chemotherapybased combinations. As IAP inhibitors have recently entered phase 1 clinical trials, 32 it is a timely question to develop combination protocols with these compounds to exploit synergistic drug actions. Combinations with conventional chemotherapeutic agents offer the advantage that such combinations might rapidly be translated into clinical practice. In conclusion, IAP inhibitors combined with chemotherapy present a promising new strategy for apoptosis-targeted therapies of pediatric ALL, which warrants further exploitation. 
